Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?

Abstract excerpt

The number of newly discovered oncogenic molecular alterations has increased dramatically during recent years. A large number of such relevant oncogenic molecular alterations occur in a small percentage of patients and define a specific segment of the disease. Disease segmentation in rare molecular entities is also related to a combination of frequent events. For example, ERBB2 amplification and PIK3CA mutations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations